PD-Rx Pharmaceuticals Recalls Azithromycin 500 mg Tablets for cGMP Deviations
PD-Rx Pharmaceuticals is recalling Azithromycin 500 mg tablets because the original manufacturer did not adequately investigate customer complaints, resulting in cGMP deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is a reasonable probability of temporary or medically reversible adverse health consequences. The specific issue is a cGMP deviation regarding the investigation of customer complaints, which is a quality control failure rather than a direct, reported physical hazard like contamination or mislabeling of a common allergen.
Plain-English summary
PD-Rx Pharmaceuticals, Inc. is recalling Azithromycin 500 mg tablets, prescription only, packaged in 1, 2, 3, and 7 count bottles. The product was manufactured by Wokhardt Ltd. in Mumbai, India, and packaged by PD-Rx Pharmaceuticals in Oklahoma City, Oklahoma. A total of 17,533 bottles were distributed nationwide.
The recall is the result of cGMP (Current Good Manufacturing Practice) deviations. Specifically, the original manufacturer did not adequately investigate customer complaints. This failure to investigate complaints constitutes a deviation from required manufacturing and quality control standards.
Consumers and healthcare providers should stop using the affected Azithromycin 500 mg tablets and return them to the pharmacy or point of purchase. The affected lots include specific lot numbers and expiration dates ranging from October 2014 to December 2015, as detailed in the recall notice.
The recalled product
- Product
- Azithromycin 500 mg tablets, Rx Only, packaged in a) 1 count, b) 2 count, c) 3 count, and d) 7 count bottles, Packaged by: PD-RX Pharmaceuticals, Inc., Oklahoma City, OK 73127, Mfr: Wokhardt Ltd., Mumbai, India, NDC: a) 55289-274-79, b) 55289-274-02, c) 55289-274-03, d) 55289-274
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Category
- Drug — Antibiotic
- Affected units
- 17,533
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #s: J12C03
- J12D19
- Exp 10/14
- L12B52
- L12E79
- L12G92
- Exp 12/14
- A13G14
- A13H49
- Exp 01/15
- B13G53
- Exp 02/15
- D13A66
- Exp 04/15
- E13E35
- Exp 05/15
- F13A58
- F13D85
- F13F17
- F13F27
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by PD-Rx Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · PD-Rx Pharmaceuticals, Inc.
See all →- HighDULoxetine tablets recalled for excess nitrosamine impurity
FDA (Drugs) · 2025-01-01
- ModerateSimvastatin USP Tablets Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-05-10
- ModerateDrug Recall: Montelukast Sodium Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-05-10
- ModerateDrug Recall: Glimepiride 4 mg for Manufacturing Practice Deviations
FDA (Drugs) · 2023-05-10
- ModerateSimvastatin 40 mg recalled nationwide for manufacturing quality deviations
FDA (Drugs) · 2023-05-10
Same hazard · cGMP deviation
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- SevereLubricant Eye Drops Solution recalled due to sterility assurance concerns
FDA (Drugs) · 2025-05-14